RxDoctor Payments Data

Umashankar Lakshmanadoss, MD

Clinical Cardiac Electrophysiology · Mesa, AZNPI 1447440474

Payments from drug & device makers

What this record shows

19 manufacturers reported payments, led by Medtronic at 58.7% of the total. 2025 is the largest year on record at $4,595, 9.2 times the $501 reported in 2019. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in AZ, where the typical reported total is $29,180.

$12,012in general payments, 2019–2025

Across 143 payments — averaging $84.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Biosense Webster, Inc.$1K
  • Abbott$1K
  • Medical Device Business Services, Inc.$1K
  • Boston Scientific$239
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$160
  • plus $792 from 13 others

What the payments were for

  • Travel & lodging$6,13051%
  • Food & beverage$5,88249%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,012 in reported general payments places this provider in the 30th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$205,740
Medicare patients
745
Services billed
3,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban210$198,170
EntrestoSacubitril/Valsartan30$27,448
XareltoRivaroxaban28$26,853
Flecainide Acetate193$8,027
Dofetilide17$2,371
Amiodarone Hcl69$1,923
Metoprolol Succinate147$1,532
Diltiazem 24hr Er (Cd)Diltiazem Hcl61$1,407
Metoprolol Tartrate40$310
SotalolSotalol Hcl11$273
Verapamil ErVerapamil Hcl12$242
Furosemide50$150
Warfarin Sodium22$143
Losartan Potassium14$122
Lisinopril30$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$87$198,170210 claims
NovartisEntresto$144$27,44830 claims
Johnson & JohnsonXarelto$47$26,85328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →